Please ensure Javascript is enabled for purposes of website accessibility

Thicker Lashes, Fatter Wallets

By Brian Orelli, PhD - Updated Apr 5, 2017 at 7:53PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Allergan's batting its eyes at you.

Watch out Bare Escentuals (NASDAQ:BARE) and Estee Lauder (NYSE:EL), there's a new kid on the market trying to smear your mascara.

On Friday, the Food and Drug Administration approved Allergan's (NYSE:AGN) Latisse, a treatment for hypotrichosis of eyelashes -- that means sparse eyelashes, for those not vain enough to know.

Small eyelashes are far from a small market -- the global market is around $3.7 billion. But Allergan is going to have a hard time capturing much of that market in this economy, considering the drug will run $120 a month. You have to look no further than how poorly cosmetic-laser makers like Syneron Medical (NASDAQ:ELOS) and Palomar Medical (NASDAQ:PMTI) have been doing over the last couple of years to see that beauty treatments are among the first things to be cut when the paycheck is in jeopardy.

But this economy will eventually rebound and Allergan could ultimately hit its target of $500 million per year in sales once the vainness returns. By comparison, Allergan is expecting nearly $1.3 billion in sales from Botox this year.

Ironically, Latisse was originally designed to treat glaucoma and is sold under the brand name Lumigan, but the longer eyelashes were discovered as a side effect. It's not all that weird to have the same active ingredient sold under two brand names. For instance Pfizer's (NYSE:PFE) Viagra is also sold as Revatio, a treatment for pulmonary arterial hypertension (PAH). The different packaging probably costs the companies a little money, but it avoids sending doctors a mixed message from their sales reps about drugs doing four different things like Eli Lilly's (NYSE:LLY) antidepressant-turned-fibromyalgia-treatment Cymbalta.

Being dependent on discretionary spending, Allergan is likely to continue to tread water until the economy improves, but investors thinking about the long term don't really need to worry about their mascara running; they can ride the waves without crying.

Syneron Medical is a selection of the Motley Fool Hidden Gems Pay Dirt and Rule Breakers services. Bare Escentuals is a recommendation of both Motley Fool Hidden Gems and Rule Breakers. Pfizer and Eli Lilly are Income Investor recommendations. Pfizer is also an Inside Value selection and the Fool owns shares. Try any of our Foolish newsletters today, free for 30 days

Fool contributor Brian Orelli, Ph.D., doesn't own shares of any company mentioned in this article. The Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Eli Lilly and Company Stock Quote
Eli Lilly and Company
$302.50 (0.39%) $1.18
Pfizer Inc. Stock Quote
Pfizer Inc.
$49.57 (0.61%) $0.30
The Estee Lauder Companies Inc. Stock Quote
The Estee Lauder Companies Inc.
$270.16 (-0.21%) $0.58
Syneron Medical Ltd. Stock Quote
Syneron Medical Ltd.
Bare Escentuals, Inc. Stock Quote
Bare Escentuals, Inc.

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/08/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.